AbbVie Inc. Stock Performance
AbbVie Inc. shares closed at $274.31, reflecting a single-session decline of 1.32% per SID market data. Despite the daily pullback, the stock has demonstrated consistent strength across multiple timeframes, gaining 4.81% over the past month, 12.39% over three months, and 19.3% over the trailing twelve months. The stock trades well above key moving averages, with its current price sitting 5.47% above the 50-day moving average of $260.08 and 17.35% above the 200-day moving average of $233.76, according to SID market data. The 14-day relative strength index registers at 62.5, indicating momentum that remains constructive without entering overbought territory. AbbVie carries a notably low beta of 0.334, underscoring its defensive characteristics relative to the broader market. Average daily trading volume stands at approximately 6.4 million shares, supporting a market capitalization of roughly $410 billion.
AbbVie Inc. Valuation Analysis
AbbVie Inc. currently trades at a trailing price-to-earnings ratio of 97.75, a figure significantly elevated relative to Healthcare sector peers, according to SID market data. This elevated P/E reflects the impact of substantial amortization charges and acquisition-related expenses on reported GAAP earnings rather than deteriorating core profitability. The PEG ratio stands at 1.25, suggesting the stock's valuation is more reasonable when adjusted for projected earnings growth, per SID market data. AbbVie's price-to-book ratio registers as negative at -126.33, a consequence of accumulated goodwill write-downs and aggressive share repurchase programs that have driven book value into negative territory, as reflected in SEC filings. The company maintains a dividend yield of 2.87%, reinforcing its appeal among income-focused investors. AbbVie has a long track record of consecutive dividend increases, positioning it as one of the higher-yielding large-cap Healthcare names available to investors seeking stable cash returns.
Smart Money Activity for ABBV
AbbVie Inc. carries an overall smart money score of 59, reflecting a neutral signal according to SID market data. The institutional component scores a perfect 25 out of 25, indicating robust and broad-based ownership among major fund managers, per 13F institutional filings. The insider trading component also scores highly at 21 out of 25, supported by two insider purchases and zero insider sales recorded over the past 90 days according to SEC Form 4 filings. This buy-only insider activity suggests corporate executives maintain confidence in AbbVie's forward trajectory. Conversely, the dark pool activity score is notably lower at 9.8 out of 25, indicating relatively subdued off-exchange institutional accumulation in recent periods. Congressional trading activity registers at just 3.2 out of 25, reflecting minimal disclosed trading by members of Congress. The divergence between strong institutional and insider signals and weaker dark pool and congressional metrics produces the composite neutral reading, though the insider buying pattern remains a constructive data point for shareholders.
AbbVie Inc. Earnings Outlook
AbbVie Inc.'s most recent quarterly results showed earnings per share of $2.65 against a consensus estimate of $2.66, representing a marginal miss of $0.01 per company earnings reports. The preceding quarter also reflected a slight shortfall, with actual EPS of $3.65 falling $0.12 below the $3.77 analyst estimate. Looking ahead, consensus estimates project EPS of $3.01 for the upcoming reporting period scheduled for April 24, while the subsequent quarter ending October 30 carries an estimate of $3.79, according to analyst estimates. The sequential step-up from $3.01 to $3.79 in projected earnings reflects anticipated contributions from AbbVie's immunology portfolio, including Skyrizi and Rinvoq, which continue to offset Humira biosimilar erosion. The back-to-back narrow misses in recent quarters suggest the company is navigating a transitional period, and investors will closely monitor whether the forward estimates adequately capture the trajectory of its growth drivers.
Wall Street Analyst Ratings for ABBV
Wall Street coverage of AbbVie Inc. reflects a broadly constructive consensus, with the majority of recent analyst actions reiterating positive ratings, per SID consensus data. On October 8, both Cantor Fitzgerald and JP Morgan maintained Overweight ratings, while Morgan Stanley reiterated its Overweight designation on October 7, according to Wall Street analyst reports. Guggenheim reaffirmed a Buy rating on October 9, further reinforcing bullish institutional sentiment. The sole outlier among recent coverage updates is UBS, which maintained a Neutral stance on October 9, representing the most cautious view among the five most recent analyst actions. Notably, none of the recent updates involved downgrades; all five were reiterations of existing positions, suggesting analysts view AbbVie's current trajectory as consistent with prior expectations. The concentration of Overweight and Buy ratings from major firms including JP Morgan, Morgan Stanley, and Cantor Fitzgerald indicates broad institutional confidence in AbbVie's strategic positioning within the large-cap biopharmaceutical landscape.
